Abivax held its Annual Ordinary and Extraordinary General Meeting on June 9th. The resolutions presented by the Board of Directors were adopted and in particular, the approval of the financial statements for the year ended December 31, 2021, the compensation policy applicable to the Chairman of the Board of Directors, the Chief Executive Officer and the directors, as well as the delegations granted to the Board administration in financial matters.
The Meeting also approved the renewal of the directorships of Jean-Jacques Bertrand, Pr. Carol L. Brosgart, MD, Joy Amundson and of Sofinnova Partners.